FDA Approves Darolutamide Plus ADT for mCS Prostate Cancer

EU Commission Approves Opdivo Regimen for High-Risk Resectable NSCLC

FDA Approves First Blood Test for Alzheimer’s, Marking a Historic Shift in Early Detection

FDA Approves Emrelis as the First Targeted ADC for High c-Met Expressing Lung Cancer

Avutometinib Earn Accelerated FDA Approval for Ovarian Cancer

FDA Announces AI Strategy with First AI-Assisted Scientific Pilot for Drug Review

Adcentrx’s Nectin-4 ADC, ADRX-0706, Earns FDA Fast Track for Cervical Cancer

First AI-Driven Diagnostic Tool Wins FDA Breakthrough Designation for Lung Cancer

FDA Approves Tislelizumab Plus Chemotherapy for PD-L1+ Metastatic Esophageal Cancer

CHMP Recommends Durvalumab Combination for EU Approval in Resectable NSCLC

Enhertu Gains EMA’s CHMP Support for HER2-Low Metastatic Breast Cancer Treatment

KEYTRUDA Receives Priority FDA Review for Perioperative Use in ES Head and Neck Cancer

Odronextamab Gains FDA Review for Hard-to-Treat R/R Follicular Lymphoma

FDA Approves Innovative ADC Datroway for Metastatic HR+, HER2- Breast Cancer

FDA Approves Sotorasib and Panitumumab Combo for KRAS G12C+ Colorectal Cancer

FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer

FDA Grants Priority Review to Datopotamab Deruxtecan for EGFR+ Lung Cancer

First-Ever Obstructive Sleep Apnea Drug, Zepbound, Approved by FDA for Obesity

FDA Approves BRAFTOVI Combo as First-Line Treatment for Colorectal Cancer

FDA Grants Breakthrough Status to Datopotamab Deruxtecan for EGFR+ Lung Cancer

Promising Sac-TMT Receives FDA Breakthrough Therapy Designation for Lung Cancer

Durvalumab Granted FDA Priority Review for Muscle-Invasive Bladder Cancer Patients

FDA Approves Durvalumab as the First and Only Immunotherapy for LSSC Lung Cancer

FDA Grants Accelerated Approval to Bizengri for NRG1+ Pancreatic Cancer and NSCLC

The FDA Approves IMKELDI, the First Oral Liquid Form of Imatinib, for Leukemia

FDA Approves First Targeted Therapy for IDH-Mutant Glioma with Companion Diagnostic

FDA Approves VYLOY™ as a New Targeted Therapy for Advanced Gastric and GEJ Cancer

AI-Powered Cancer Drug LP-184 Receives FDA Fast-Track Designation for Glioblastoma

FDA Approves TruSight Cancer Test for Matching Patients with Targeted Therapies

Nipocalimab Submitted to FDA for Treatment of Generalized Myasthenia Gravis